Form 4: Actuate Therapeutics Insider Transactions: Bios Equity Partners and Director Fletcher Report Ownership Changes Following IPO

Following Actuate Therapeutics' IPO, director Aaron G.L. Fletcher and related entities including Bios Equity Partners reported conversions of preferred stock and notes into common stock, along with warrant exercises and option grants.

Summary

• This Form 4 filing details changes in beneficial ownership of Actuate Therapeutics, Inc. (ACTU) securities by director Aaron G.L. Fletcher and related entities, including various Bios Equity Partners funds.
• The transactions occurred following Actuate Therapeutics' IPO and involve the conversion of convertible notes and preferred stock into common stock.
• Warrants to purchase common stock were also exercised on a cashless basis.
• Fletcher was granted 15,000 stock options exercisable beginning August 12, 2025.
• The filing covers multiple entities and transactions, necessitating multiple Form 4 filings due to SEC limitations on the number of reporting persons and rows per form.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The conversions and warrant exercises are expected events following the IPO and suggest confidence in the company's future. However, the small sales of shares by some Bios funds temper the overall positive sentiment.

Positives

• The conversion of preferred stock and notes into common stock indicates confidence in the company's future following the IPO.
• The exercise of warrants suggests a belief that the stock price will remain above the exercise price of $5.27.
• The grant of stock options to a director aligns their interests with those of the shareholders.

Negatives

• The sale of shares by Bios Fund II, LP, Bios Fund II QP, LP, and Bios Fund II NT, LP at $9 could be interpreted as a lack of confidence in further price appreciation, although the amounts are relatively small.
• The complexity of the ownership structure and multiple entities involved could make it difficult for investors to fully understand the transactions.

Risks

• The large number of shares held by insiders could create potential for future sales that could negatively impact the stock price.
• The vesting of Fletcher's stock options is contingent upon his continued service, creating a potential risk if he were to leave the company.
• The warrants held by Bios Funds expire at the earliest of September 7, 2028, a change in control, or August 14, 2026, potentially creating selling pressure as the expiration date approaches.

Future Outlook

The document does not contain explicit forward-looking statements, but the transactions suggest a belief in the company's prospects following the IPO.

Industry Context

Form 4 filings are standard practice after an IPO and provide transparency into insider ownership and transactions. The conversions of preferred stock and notes are typical events following an IPO, as these securities are often designed to convert into common stock upon a public offering.

Comparison to Industry Standards

• The conversion ratios and warrant exercise prices are specific to the terms negotiated in Actuate Therapeutics' financing agreements, making direct comparisons difficult.
• Cashless warrant exercises are a common mechanism to avoid the need for warrant holders to provide additional capital.
• The vesting schedule for Fletcher's stock options is typical for director grants, aligning their interests with long-term shareholder value.

Stakeholder Impact

• The conversions and warrant exercises dilute existing shareholders to a small degree.
• The increased transparency of insider ownership benefits all stakeholders by providing a clearer picture of the company's ownership structure.

Key Dates